

**A MINI REVIEW OF GASTROINTESTINAL PATHOLOGY AND NUTRITION IN
AUTISM SPECTRUM DISORDER**

ABSTRACT

Autism spectrum disorder (ASD) is a complex, heterogenous group of neurodevelopmental disorders that result due to interaction of genes and environmental factors. ASD is associated with behavioural alterations and deficits in social communication. Current research on pathophysiology has proposed a link between severity of symptoms of ASD and gastrointestinal disturbances. Intestinal inflammation, dysregulation of gut microbiome may affect intestinal permeability, mucosal immune function and subsequently cause GI symptoms. Studies have also proposed the role of metabolic activity of the gut microbiome and dietary components (food allergens/toxins) to be associated with behavioral alterations in neurodevelopmental conditions including ASD. The present review aims to highlight the potential role of nutrients and dietary changes on gastrointestinal pathology and symptoms of ASD.

Key Words: Autism Spectrum Disorder, Gastrointestinal, Diet, Nutrients

INTRODUCTION

Autism spectrum disorder (ASD) is a neurodevelopmental condition presenting with restricted, repetitive patterns of behaviors, interests, and activities, or persistent deficits in social communication and interaction. The Diagnostic and Statistical Manual of Mental Disorders (DSM), 2013 now classifies all individuals previously diagnosed with Autism, Asperger's Syndrome, Pervasive Developmental Disorder not otherwise specified under the umbrella of Autism Spectrum Disorder.

Autism Spectrum Disorder has strong genetic basis with several genes, Gamma-aminobutyric acid (GABA) A receptor, Beta 3 (GABRB3), Oxytocin receptor (OXTR), N-methyl-D-aspartate receptor (NMDA; GRIN2B) to name a few, being consistently implicated in pathogenesis of the condition. Recent studies, however, have described a number of environmental, non genetic factors and associated disturbances in gastrointestinal and immune systems in the pathophysiology of ASD. These factors may have a direct link in the pathogenesis or may act as 'gene modifiers' thereby aggravating the primary causative mechanism [1]. Several research groups have studied the link between intestinal mucosal permeability, abnormal gut development, gastroesophageal reflux and intestinal infections in ASD with inconclusive results regarding cause or effect relationship of the mentioned factors [2, 3, 4]. Research is also being conducted to analyze the role of diet and nutrition in ASD, with attention being focused on food allergens, toxicity, and sensitivity. The present review aims to highlight the potential role of nutrients and dietary changes on gastrointestinal pathology and symptoms of ASD.

39

40 **Role of maternal factors and breastfeeding in ASD**

41 Prenatal maternal factors such as lifestyle, nutritional status especially during critical periods of
42 fetal neurodevelopment have been shown to be associated with higher risk of ASD [5]. Post-
43 natally, breastfeeding has been described as a chief environmental factor affecting the chance of
44 occurrence of ASD [6]. Protective effects of breastfeeding on the developing GI tract have been
45 described with, shorter duration of breastfeeding (less than 6 months) being associated with
46 increased chance of infants developing ASD. Data from parent interview-based studies revealed
47 early occurrence of GI symptoms (within 2-3 years of age) in children diagnosed with ASD,
48 especially in those who were fed with infant formula and bovine milk [7, 8, 9].

49 Protein content of breast milk is low compared to bovine milk and infant formula products. Of
50 the two protein components in milk-casein and whey, casein has a tendency to curdle thereby
51 becoming more difficult to digest subsequently leading to GI symptoms in the infant such as
52 constipation or diarrhea and abdominal pain. Breast milk is low in casein, which protects the
53 infant from GI disturbances. Additionally, bioactive agents present in breast milk aid in
54 development of the brain and immune system [10].

55 *Dietary considerations:*

56 Exclusive breastfeeding for the first 6 months of life will aid in optimal growth and development
57 of the infant, while preventing occurrence of GI symptoms thereby reducing exacerbation of
58 neurological symptoms of autism. The WHO recommends continuation of breastfeeding for up
59 to 2 years of age along with introduction of solid food items. Substituting bovine milk with
60 coconut or soya milk may aid in reducing severity of symptoms in children with ASD.

61

62 **Gut-Brain Axis**

63 Dysregulation in the gut microbiome and subsequent metabolic activity have been suspected to
64 alter behavior and cognition in several neurodegenerative diseases, such as Alzheimers disease,
65 Parkinson's disease etc. Thus, it may be hypothesized that gastrointestinal factors may play a
66 role in neuroinflammation and subsequent brain dysfunction in ASD [11]. There exists a bi-
67 directional communication between the gut and the brain which involves afferent and efferent
68 pathways. The afferent pathway includes cytokines, intestinal hormones and microbiota while
69 the efferent pathway includes neuro-endocrine and autonomic regulation [12]. The gut-brain axis
70 plays a role in modulation of body metabolism through regulation of appetite and energy
71 homeostasis as well as behavioral factors such as response to stress and pain, emotions and
72 attitude etc.

73 The homology between the gut-blood barrier and blood-brain barrier has been suggested to play
74 an important role in communication between the gut and brain [11]. Disruption of integrity of
75 either barrier due to activity of inflammatory mediators may be associated with systemic
76 dissemination of toxins. In context of ASD, neurotropic viruses or bacterial toxins from the
77 intestine may reach the CNS through enteroendocrine cells or directly via vagus nerve, thereby
78 causing aggravation of symptoms of the condition [13, 14].

79 Diarrhea, constipation, abdominal pain, gaseousness are commonly reported gastrointestinal
80 symptoms in patients with ASD. Presence of IgG-class antibodies directed against food antigens
81 has been considered as indirect evidence of increased intestinal permeability. A study done by
82 Lau et al. (2013) reported that children with autism have significantly higher levels of IgG
83 Antigliadin Antibodies (but not IgA) compared with healthy controls, particularly those with
84 gastrointestinal symptoms [15]. Recent studies confirmed these findings and also reported an

85 increase in antibodies directed to several other food allergens, including casein and whole milk
86 [16].

87

88 *Role of intestinal microorganisms*

89 Studies have reported overgrowth of obligate anaerobic organisms such as Clostridium spp. as
90 well as Vibrio spp. in children with autism [14, 17]. These organisms do not breakdown
91 fermentation end products such as short chain fatty acids-propionate, butyrate and acetate.
92 Propionic acid especially has been detected in high levels in stool and urine samples of patients
93 with ASD. Short chain fatty acids are capable of crossing the gut-blood and blood-brain barriers,
94 thereby may be associated with symptoms of developmental delay, seizures along with GI
95 manifestations in ASD [18].

96

97 *Dietary considerations*

98 Dietary modifications based on identification of GI factors/symptoms, may aid treatment
99 planning and in alleviating pain, constipation/diarrhea and other symptoms as well as improve
100 non verbal behaviors (agitation, anxiety, aggression, self-injury, sleep deprivation) as seen in
101 ASD. In addition, a low carbohydrate diet that would reduce the production of short chain fatty
102 acids may be advised in ASD. Studies have suggested a link between intestinal microbiota and
103 metabolism in children with ASD and hyperoxalemia/hyperoxaluria [19]. Impaired oxalate
104 metabolism may be associated with increased GI permeability and decreased intestinal
105 microflora, which as described earlier may result in aggravation of neurological symptoms of
106 ASD. It would therefore be advisable to avoid foods high in oxalates such as berries, grapes,
107 apples; millets, oats; and nuts.

108

109 *Gluten sensitivity in ASD*

110 In order to prevent/ameliorate GI and neurological manifestations, it is imperative to identify
111 trigger food items and follow a restriction/elimination diet. Gluten, a protein complex, found in
112 cereals such as wheat, barley, rye etc. has been implicated in the pathogenesis of several
113 intestinal disorders [20]. Several research groups have studied the effect of gluten in ASD with
114 conflicting results [21, 22, 23]. One aspect to be considered in the pathogenesis of ASD is the
115 opioid phenotype of autism that is linked to 'exorphins'- food related oligopeptides. Exorphins
116 are derived from incompletely digested gluten and/or casein due to reduced activity of dipeptidyl
117 peptidase-4 (DPP-4) enzyme [24]. These exogenous opioid peptides may influence GI functions
118 and may also elicit behavioral changes through their effects on dopaminergic, serotonergic and
119 GABAergic systems in the brain [25]. It may thus be hypothesized that a gluten-free, casein-free
120 (GFCCF) diet may reduce production of exorphins and prevent development or worsening of
121 symptoms of ASD.

122 De Magistris et al. (2010) reported a high percentage of abnormal intestinal permeability test
123 values [as established by the lactulose/mannitol (L/M) ratio] among patients with autism [26].
124 The study observed that patients with autism on a reported GFCCF diet had significantly lower
125 intestinal permeability test values compared with those who were on an unrestricted diet and
126 controls. However, despite the increasing popularity, efficacy of the GFCCF diet in improving
127 autistic behavior remains to be proven. A Cochrane review (2008) reported that only two small
128 randomized controlled trials investigated the effect of the GFCCF diet in children with ASD (n =
129 35) [27]. The review concluded, based on the outcomes evaluated (overall autistic traits, social

130 isolation, and overall ability to communicate and interact), that the evidence for efficacy of such
131 an exclusion diet is poor, and large-scale good-quality randomized controlled trials are needed to
132 validate the results [27]. Similar conclusions were reported by a recently published systematic
133 review on treatment of autistic children with the GFCF diet [10]. However, in a two-stage
134 randomized controlled study of the GFCF diet in children with ASD, Whiteley et al. (2010)
135 reported significant group improvements in core autistic and related behaviors after 8 and 12
136 months [28].

137 Several potential factors appear to influence response to dietary intervention in terms of
138 symptom presentation. Age was found to be the strongest predictor of response, and participants
139 between 7 and 9 years of age seemed to derive most benefit from the GFCF dietary intervention
140 [29]. The above data suggest that removing gluten from the diet may positively affect the clinical
141 outcome in some children diagnosed with ASD. Based on the findings, it may also be suggested
142 that autism may be part of the Non-celiac gluten sensitivity spectrum, at least in some cases.

143

144 **Nutritional deficiencies in ASD**

145 Pathogenesis of ASD may begin during fetal developmental stages. As previously explained,
146 maternal nutrition plays an important role in brain development and deficiencies have been
147 reported to be associated with adverse neurodevelopmental outcomes [30]. Nutritional
148 deficiencies may be caused due to increased fetal metabolic demands or pre-existing maternal
149 health conditions which directly influence structural and functional brain development, thus
150 increasing the risk of ASD [31]. Maternal vitamin A, D, folate, Vitamin B12, magnesium,
151 omega-3 fatty acid and iron supplementation has been shown to protect the developing brain
152 from inflammatory changes, neurotoxins and enhance neuronal development [5].

153 Studies have reported feeding problems, food selectivity, unusual eating patterns in patients with
154 ASD [32]. Additionally, significant associations have been found between oral-motor,
155 gastrointestinal and sensory problems in children with ASD. Dietary supplementation of
156 essential nutrients is therefore widely employed in children with ASD to aid in growth and
157 development, as well as prevent worsening of ASD status.

158

159 *Dietary considerations:*

160 *Vitamin B12 and Folic acid*

161 Studies have reported low methionine, homocysteine, cysteine in children with ASD.
162 Additionally, reduced antioxidant capacity and abnormal trans-sulfuration metabolism have also
163 been reported. Supplementation of vitamin B12 was found to elevate methylation capacity and
164 improve 'redox status', thus improving clinical behavioral outcomes in children with ASD [33].
165 Vitamin B12 is naturally found in animal products such as, fish, meat, poultry, milk and milk
166 products but generally absent in plant foods. Moreover, an inherent drawback of dietary vitamin
167 B12 supplementation is that, oral absorption is less effective and does not guarantee adequate
168 concentrations. Therefore, further studies are required to identify the most appropriate route of
169 supplementation of vitamin B12 in patients with ASD.

170 Similarly, folic acid, which is a reduced form of folate, plays a role in the metabolism of
171 homocysteine and glutathione, similar to Vitamin B12. Folic acid is naturally found in foods
172 such as, chickpeas, beef liver, asparagus etc. A recent RCT reported improvement in verbal
173 communication after supplementation of folic acid in patient with ASD [34].

174

175 *Vitamin D*

176 Vitamin D is a fat soluble agent that plays the role of a ‘neuroactive steroid’ during brain
177 development. The vitamin aids in cell proliferation and differentiation, calcium signaling and
178 exerts neurotrophic and neuroprotective effects. Vitamin D also plays an essential role in
179 myelination, thus may have effects on synaptic plasticity and neurotransmission [35]. In context
180 of ASD, the plausible mechanism of action of vitamin D are: anti-inflammatory effects on the
181 brain, and regulation of serotonin. In an RCT done by Saad et al. (2018), improvement in
182 behavioral measures (Autism Evaluation Checklist, CARS, SRS) was observed 4 months after
183 supplementation of vitamin D in children with ASD [36]. Sunlight is the best source of vitamin
184 D, however, cheese, egg yolk, fatty fish such as tuna, salmon also provide the vitamin. Studies
185 have reported improvement in core symptoms of autism, thus dietary supplementation must be
186 considered, especially in autistic children with deficiency of vitamin D.

187 188 *Omega-3 fatty acids*

189 The two omega-3 fatty acids: Eicosapentanoic acid (EPA) and Docosahexanoic acid (DHA),
190 play an important role in normal growth and development of the body, including
191 neurodevelopment. Low concentrations of EPA and DHA have been observed in patients with
192 ASD as well as other neurodevelopmental anomalies, considering that these orthomolecules have
193 functional sites exclusively on cell membranes, including nerve cells [37]. Although, data from
194 clinical trials have not directly reported benefits of omega-3 fatty acids in core symptoms of
195 ASD, supplementation was safe and well tolerated and was found to benefit general
196 neurodevelopment in children [38, 39].

197 198 *Probiotics*

199 Probiotics are live microorganisms (bacteria and yeast) that provide health benefits by restoring
200 or improving normal gut microbiota. Probiotic therapy has been proposed as a relatively risk-
201 free, adjuvant modality to ameliorate gastrointestinal symptoms in patients with ASD [40].
202 Supplementation has been demonstrated to increase counts of Lactobacilli and Bifidobacterium
203 spp., which improve both GI and core behavioral symptoms of ASD [41]. However, most studies
204 are associated with the limitation of small sample size; therefore, future research should be
205 conducted on a larger scale in order to accurately elucidate the effect of probiotics in patients
206 with ASD.

207 208 **CONCLUSION**

209 Identification of trigger foods and dietary modification in ASD is a gradual process and may
210 differ between affected individuals. The present review highlights some of the common food
211 allergens and nutrients/nutritional deficiencies responsible for exacerbation of symptoms of
212 ASD. Further research is required to establish the effects of these agents as well as identify other
213 probable food toxins and allergens affecting the pathology of autism spectrum disorder.

214 **COMPETING INTERESTS**

215 Authors have declared that no competing interests exist.

216 217 **COMPETING INTERESTS DISCLAIMER:**

218 Authors have declared that no competing interests exist. The products used for this research are
219 commonly and predominantly use products in our area of research and country. There is

220 absolutely no conflict of interest between the authors and producers of the products because we
221 do not intend to use these products as an avenue for any litigation but for the advancement of
222 knowledge. Also, the research was not funded by the producing company rather it was funded by
223 personal efforts of the authors.

224

225

226 REFERENCES

- 227 1. Samsam M, Ahangari R, Saleh AN. Pathophysiology of autism spectrum disorders:
228 Revisiting gastrointestinal involvement and immune imbalance. *World J Gastroenterol* 2014
229 August 7; 20(29): 9942-9951.
- 230 2. Buie T, Campbell DB, Fuchs GJ III, Furuta GT, Levy J, Vandewater J, et al. Evaluation,
231 diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus
232 report. *Pediatrics*. 2010;125(suppl 1):S1–S18.
- 233 3. Samsam M. *Functionally Oriented Regional Anatomy*. 2nd ed. Plymouth, MI: Hayden
234 McNeil publishing, 2013: 209-302.
- 235 4. Williams BL, Hornig M, Buie T, Bauman ML, Cho Paik M, Wick I, et al. Impaired
236 carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with
237 autism and gastrointestinal disturbances. *PLoS ONE*. 2011;6(9): e24585.
- 238 5. Lyall K, Schmidt RJ, Hertz-Picciotto I. Maternal lifestyle and environmental risk factors for
239 autism spectrum disorders. *International Journal of Epidemiology*, 2014, 443–464.
- 240 6. Schultz ST, Klonoff-Cohen HS, Wingard DL, Akshoomoff NA, Macera CA, Ji M, et al.
241 Breastfeeding, infant formula supplementation, and Autistic Disorder: the results of a parent
242 survey. *Int Breastfeed J*. 2006; 1:16.
- 243 7. Horvath K, Perman JA. Autism and gastrointestinal symptoms. *Curr Gastroenterol Rep*.
244 2002; 4(3):251–258.
- 245 8. Dominick KC, Davis NO, Lainhart J, Tager-Flusberg H, Folstein. Atypical behaviors in
246 children with autism and children with a history of language impairment. *Res Dev Disabil*.
247 2007; 28(2):145–162.
- 248 9. Penn AH, Carver LJ, Herbert, Lai TS, McIntire MJ, Howard JT et al. Breast Milk Protects
249 Against Gastrointestinal Symptoms in Infants at High Risk for Autism During Early
250 Development. *J Pediatr Gastroenterol Nutr*. 2016 February; 62(2): 317–327.
- 251 10. Schultz ST, Klonoff-Cohen HS, Wingard DL, Akshoomoff NA, Macera CA, Ji M, et al.
252 Breastfeeding, infant formula supplementation, and Autistic Disorder: the results of a parent
253 survey. *Int Breastfeed J*. 2006; 1:16.
- 254 11. Wasilewska J, Klukowski M. Gastrointestinal symptoms and autism spectrum disorder: links
255 and risks – a possible new overlap syndrome. *Pediatric Health, Medicine and Therapeutics*
256 2015;6 153–166
- 257 12. Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. *J Clin Invest*.
258 2015;125(3):926–938.
- 259 13. Theoharides TC, Zhang B. Neuro-inflammation, blood-brain barrier, seizures and autism. *J*
260 *Neuroinflammation*. 2011;8:168.
- 261 14. Bolte ER. Autism and *Clostridium tetani*. *Med Hypotheses*. 1998; 51(2):133–144.

- 262 15. Lau NM, Green PH, Taylor AK, Hellberg D, Ajamain M, Tan CZ, et al. Markers of celiac
263 disease and gluten sensitivity in children with autism. *PLoS ONE*. 2013;8(6).
- 264 16. De Magistris L, Picardi A, Siniscalco D, Riccio MP, Sapone A, Cariello R. Antibodies
265 against food antigens in patients with autistic spectrum disorders. *Biomed Res Int*
266 2013;2013:729349.
- 267 17. Tomova A, Husarova V, Lakatosova S, Bakos J, Vlkova B, Babinska K, et al.
268 Gastrointestinal microbiota in children with autism in Slovakia. *Physiol Behav*.
269 2015;138:179–187.
- 270 18. Al-Owain M, Kaya N, Al-Shamrani H, Al-Bakheet A, Qari A, Al-Muaigl S, et al. Autism
271 spectrum disorder in a child with propionic acidemia. *JIMD Rep*. 2013;7:63–66.
- 272 19. Konstantynowicz J, Porowski T, Zoch-Zwierz W, Wasilewska J, Kadziela-Olech H, Kulak
273 W, et al. A potential pathogenic role of oxalate in autism. *Eur J Paediatr Neurol*.
274 2012;16(5):485–491.
- 275 20. Catassi C. Gluten Sensitivity. *Ann Nutr Metab* 2015;67(suppl 2):16–26.
- 276 21. Navarro F, Pearson DA, Fatheree N, Mansour R, Hashmi SS, Rhoads JM. Are ‘leaky gut’
277 and behavior associated with gluten and dairy containing diet in children with autism
278 spectrum disorders? *Nutr Neurosci*. 2015;18(4):177–185.
- 279 22. Whiteley P, Shattock P, Knivsberg AM, Seim A, Reichelt KL, Todd L, et al. Gluten- and
280 casein-free dietary intervention for autism spectrum conditions. *Front Hum Neurosci*.
281 2012;6:344.
- 282 23. Elder JH, Shankar M, Shuster J, Theriaque D, Burns S, Sherrill L. The gluten-free, casein-
283 free diet in autism: results of a preliminary double blind clinical trial. *J Autism Dev Disord*.
284 2006;36(3):413–420.
- 285 24. Johnson B, Ulberg S, Shivale S, Donaldson J, Milczarski B, Faraone SV. Fibromyalgia,
286 autism, and opioid addiction as natural and induced disorders of the endogenous opioid
287 hormonal system. *Discov Med*. 2014;18(99):209–220.
- 288 25. Cieslinska A, Sienkiewicz-Szlapka E, Wasilewska J, Feidorowicz E, Chawla B, Moszynska-
289 Dumara M, et al. Influence of candidate polymorphisms on the dipeptidyl peptidase IV and
290 mu-opioid receptor genes expression in aspect of the beta-casomorphin-7 modulation
291 functions in autism. *Peptides*. 2015;65C:6–11.
- 292 26. De Magistris L, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, et al. Alterations of
293 the intestinal barrier in patients with autism spectrum disorders and in their first-degree
294 relatives. *J Pediatr Gastroenterol Nutr* 2010;51:418-424.
- 295 27. Millward C, Ferriter M, Calver S, Connell-Jones G. Gluten- and casein-free diets for autistic
296 spectrum disorder. *Cochrane Database Syst Rev* 2008;2:CD003498.
- 297 28. Whiteley P, Haracopos D, Knivsberg AM, Reichelt KL, Parlar S, Jacobsen J, et al. The
298 ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary
299 intervention for children with autism spectrum disorders. *Nutr Neurosci* 2010;13:87-100.
- 300 29. Pedersen L, Parlar S, Kvist K, Whiteley P, Shattock P. Data mining the ScanBrit study of a
301 gluten- and casein-free dietary intervention for children with autism spectrum disorders:
302 behavioural and psychometric measures of dietary response. *Nutr Neurosci* 2014;17:207-213.
- 303 30. Black MM. Micronutrient deficiencies and cognitive functioning. *J Nutr* 2003;133(11 Suppl
304 2):3927S–31S.
- 305 31. Institute of Medicine. *Nutrition During Pregnancy* 1990. Washington, DC: National
306 Academy Press, 1990.

- 307 32. Nadon G, Feldman D and Gisel E. Feeding Issues Associated with the Autism Spectrum
308 Disorders. Recent Advances in Autism Spectrum Disorders - Volume I
309 33. Han Y, Xi QQ, Dai W, Yang SH, Gao L, Su YY, et al. Abnormal transsulfuration
310 metabolism and reduced antioxidant capacity in Chinese children with autism spectrum
311 disorders. *Int J Dev Neurosci* (2015) 46:27–32.
312 34. Frye R, Slattery J, Delhey L, Furgerson B, Strickland T, Tippet M, et al. Folinic acid
313 improves verbal communication in children with autism and language impairment: a
314 randomized double-blind placebo-controlled trial. *Mol Psychiatry* (2016).
315 35. Cannell JJ. Vitamin D and autism, what's new? *Rev Endocr Metab Disord* (2017) 18(2):183–
316 93.
317 36. Saad K, Abdel-Rahman AA, Elserogy YM, Al-Atram AA, El-Houfey AA, Othman HA, et al.
318 Randomized controlled trial of vitamin D supplementation in children with autism spectrum
319 disorder. *J Child Psychol Psychiatry* (2016).
320 37. Yehuda S, Rabinovitz S, Mostofsky D. Essential fatty acids and the brain: from infancy to
321 aging. *Neurobiol Aging* (2005) 26(1):98–102.
322 38. Mazahery H, Stonehouse W, Delshad M, Kruger MC, Conlon CA, Beck KL, et al.
323 Relationship between long chain n-3 polyunsaturated fatty acids and autism spectrum
324 disorder: systematic review and meta-analysis of case-control and randomised controlled
325 trials. *Nutrients* (2017) 9(2):155.
326 39. Yui K, Koshiha M, Nakamura S, Kobayashi Y. Effects of large doses of ara-chidonic acid
327 added to docosahexaenoic acid on social impairment in individuals with autism spectrum
328 disorders: a double-blind, placebo-controlled, randomized trial. *J Clin Psychopharmacol*
329 (2012) 32(2):200–6.
330 40. Shaaban SY, El Gendy YG, Mehanna NS, El-Senousy WM, El-Feki HSA, Saad K, et al. The
331 role of probiotics in children with autism spectrum disorder: A prospective, open-label study.
332 *Nutr Neurosci*. 2017 Jul 7:1-6.
333 41. Patusco R, Ziegler J. Role of Probiotics in Managing Gastrointestinal Dysfunction in
334 Children with Autism Spectrum Disorder: An Update for Practitioners. *Advances in*
335 *Nutrition*, Volume 9, Issue 5, 1 September 2018, Pages 637–650.

339

340